key: cord-0969687-prh0g82e
authors: Masumoto, Akiko; Kitai, Takeshi; Matsumoto, Shingo; Kuroda, Shunsuke; Kohsaka, Shun; Tachikawa, Ryo; Seo, Ryutaro; Doi, Asako; Tomii, Keisuke; Yonetsu, Taishi; Torii, Sho; Komuro, Issei; Hirata, Ken-ichi; Node, Koichi; Matsue, Yuya; Furukawa, Yutaka
title: Impact of serum lactate dehydrogenase on the short-term prognosis of COVID-19 with pre-existing cardiovascular diseases
date: 2021-12-28
journal: J Cardiol
DOI: 10.1016/j.jjcc.2021.12.014
sha: af33aaa8a49119c89bef7877190ec4171a4ca055
doc_id: 969687
cord_uid: prh0g82e

BACKGROUND: Patients with coronavirus disease 2019 (COVID-19) and underlying cardiovascular comorbidities have poor prognoses. Our aim was to identify the impact of serum lactate dehydrogenase (LDH), which is associated with mortality in acute respiratory distress syndrome, on the prognoses of patients with COVID-19 and underlying cardiovascular comorbidities. METHODS: Among 1,518 patients hospitalized with COVID-19 enrolled in the CLAVIS-COVID (Clinical Outcomes of COVID-19 Infection in Hospitalized Patients with Cardiovascular Diseases and/or Risk Factors study), 515 patients with cardiovascular comorbidities were analyzed. Patients were divided into tertiles based on LDH levels at admission [tertile 1 (T1), <235 U/L; tertile 2 (T2), 235-355 U/L; and tertile 3 (T3); ≥356 U/L]. We investigated the impact of LDH levels on the in-hospital mortality. RESULTS: The mean age was 70.4±30.0 years, and 65.3% were male. There were significantly more in-hospital deaths in T3 than in T1 and T2 [n=50 (29.2%) vs. n=15 (8.7%), and n=24 (14.0%), respectively; p<0.001]. Multivariable analysis adjusted for age, comorbidities, vital signs, and laboratory data including D-dimer and high-sensitivity troponin showed T3 was associated with an increased risk of in-hospital mortality (adjusted hazard ratio, 3.04; 95% confidence interval, 1.50–6.13; p=0.002). CONCLUSIONS: High serum LDH levels at the time of admission are associated with an increased risk of in-hospital death in patients with COVID-19 and known cardiovascular disease and may aid in triage of these patients.

Severe acute respiratory distress syndrome (ARDS) caused by the coronavirus disease 2019 has led to serious morbidity in hundreds of millions of individuals worldwide.

Recent reports have identified that patients with COVID-19 and underlying cardiovascular morbidities face increased mortality compared with those without cardiovascular disease [1, 2] .

Lactate dehydrogenase (LDH) could be a useful marker of systemic inflammation, as it is a cytoplasmic enzyme that is widely expressed in tissues. It has been reported that serum LDH concentrations increase during the acute lung damage that occurs in interstitial lung disease and severe respiratory failure [3] . LDH level is also one of the biomarkers most strongly associated with ARDS mortality [4, 5] . Of the various biomarkers that have been investigated for the prediction of the prognoses of patients with COVID-19, elevated LDH level is reported to be associated with increased mortality [6] [7] [8] [9] [10] . However, no previous study has focused on the significance of high LDH levels in patients with COVID-19 and underlying cardiovascular disease.

Thus, our aim of this study was to investigate the impact of LDH levels measured at the time of hospital admission on the prognoses of patients with COVID-19 and pre-existing cardiovascular comorbidities.

This study was a post-hoc analysis of the CLAVIS-COVID (Clinical Outcomes of COVID- 19 Infection in Hospitalized Patients with Cardiovascular Diseases and/or Risk Factors) study.

The design and primary results of the study have been reported elsewhere [11] with a unique description of the data of patients with COVID-19 and preexisting or developing cardiovascular diseases or coronary risk factors. Briefly, the CLAVIS-COVID study was a multicenter retrospective observational study that included 1,518 patients with COVID-19 who were hospitalized in participating institutions in Japan between January 1, 2020, and May 31, 2020. Patients under 20 years of age were excluded from the CLAVIS-COVID. For the present study, 938 patients without any pre-existing cardiovascular diseases and 65 patients without data on baseline serum LDH level at the time of hospital admission were excluded. Thus, a total of 515 patients with pre-existing cardiovascular disease on admission for COVID-19 were included. The patients were divided into three tertiles based on their serum LDH levels at the time of admission as follows: tertile 1 (T1, LDH <235 U/L), tertile 2 (T2, LDH, 235-355 U/L), and tertile 3 (T3, LDH ≥ 356 U/L).

The study protocol, including the use of an opt-out consent method, was approved by the local ethics committees of all participating institutions. This clinical study was registered with the University Hospital Medical Information Network (UMIN) Clinical Trial Registry (ID: UMIN000040598) before the first patient was enrolled, in accordance with the International Committee of Medical Journal Editors.

Patients were diagnosed with COVID-19 when a polymerase chain reaction detected severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in their test samples [12] . The decision to hospitalize a patient was made by a physician based on the patient's clinical condition, age, and comorbidities. Upon hospital admission, baseline data on medical history, medication, vital signs, symptoms, and laboratory tests were obtained.

For the purpose of this study, cardiovascular disease was defined as a history or new diagnosis of at least one of the following diseases/conditions within 30 days of COVID-19 infection: hypertension, coronary artery disease, old myocardial infarction, cerebrovascular disease, peripheral vascular disease, heart failure, moderate or severe valvular heart disease, pulmonary hypertension, congenital heart disease, cardiomyopathy, myocarditis/pericarditis, arrhythmia, venous thromboembolism, aortic disease, cardiac transplant, cardiac arrest, and implantation of a left ventricular assist device or cardiac implantable electronic device.

Patients with oxygen saturation under 92% were administered supplemental oxygen [13] .

Mechanical ventilation was initiated when patients developed respiratory failure that could not be treated with oxygen therapy. Some patients underwent non-invasive ventilation with a high-flow nasal cannula or noninvasive positive pressure ventilation at the physician's discretion. Decisions regarding the initiation, duration, and dose of antibiotic therapy, antiviral therapy, anticoagulation with heparin, and steroid therapy were made by the physicians in each institution.

The patients were followed up until the initial hospital discharge; their symptoms, inhospital clinical events, type and date of in-hospital treatment, and laboratory data before discharge were recorded. The median follow-up duration was 18 days after admission. The primary outcome measure of this analysis was in-hospital mortality. The tertiles of serum LDH levels measured on admission were analyzed and compared.

Categorical variables were expressed as numbers and percentages and were compared using the chi-square test or Fisher's exact test as appropriate. Continuous variables were expressed as either means and standard deviations or as medians and interquartile ranges and were compared using unpaired t-tests. Survival analysis was performed using Kaplan-Meier analysis, and differences among the three groups were assessed using a log-rank test. The Cox proportional hazards model was used to estimate the risk of variables to determine the predictors of the primary outcome. The following variables were selected a priori: age, sex, cardiovascular comorbidities (heart failure, coronary artery disease, old myocardial infarction, valvular heart disease, arrhythmia, cerebral infarction, hypertension, venous thromboembolism, aortic disease), non-cardiovascular comorbidities [dyslipidemia, diabetes mellitus, chronic obstructive pulmonary disease (COPD), and end-stage renal disease with hemodialysis], patient's medication at the time of admission (angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker, beta-blocker, calcium channel blocker, mineralocorticoid receptor antagonist, statin, aspirin, warfarin, direct oral anticoagulant), vital signs measured at the time of admission (tachypnea, respiratory rate ≥ 22 per minutes; hypoxia, SpO2 < 92% or the need for oxygen therapy; tachycardia, heart rate > 100 beats per minute; hypotension, systolic blood pressure <100 mmHg; and altered consciousness, Glasgow Coma Scale score < 15), risk of sepsis [quick sequential organ failure assessment (qSOFA) score ≥ 2], and baseline laboratory data [white blood cell count, lymphocyte count, hemoglobin, LDH, creatinine kinase (CK), albumin, low-density lipoprotein cholesterol, hemoglobin A1c (HbA1c), C-reactive protein, D-dimer, and high-sensitivity troponin levels].

Despite multiple possible confounders, the limited number of events led us to conduct two statistical models for the multivariable analyses, while variables were selected when they were reported to be associated with prognosis of COVID-19 patients or deemed clinically important and useful by the consensus of the authors. The multivariable analysis in Model 1 was conducted with adjustments for age, previous comorbidities, vital signs, and simplified laboratory data [estimated glomerular filtration rate (eGFR), white blood cell (WBC) count, lymphocyte count, D-dimer and LDH]. The multivariable analysis in Model 2 was conducted with adjustments for age, quick SOFA score, and general items in laboratory tests (eGFR, WBC count, lymphocyte count, D-dimer and LDH, hemoglobin, albumin, and CK). To test for effect modification, the interaction terms of age and sex and the primary outcome measure were evaluated with Cox regression models where they were included together. In all analyses, a p-value <0.05 was considered significant. All statistical analyses were performed using SPSS Statistics (version 25.0; IBM Corp., Armonk, NY, USA). and T2 (1.6% vs. 14.7% and 4.2%, respectively; p < 0.001).

The median length of hospital stay was 18 (IQR 11, 28) days after admission to the hospital.

The primary and secondary outcome measures recorded in each tertile of serum LDH level are shown in Figure 2 . There were significantly more in-hospital deaths in T3 than in the other tertiles (T1 vs. T2 vs. T3, 10.5% vs. 13.4% vs. 42.1%; p < 0.001). Figure 3 shows the Kaplan-Meier curves of in-hospital mortality in each tertile of LDH levels. The in-hospital mortality 30 days after initial hospitalization in T1, T2, and T3 was estimated as 8.6%, 16.5%, and 27.8%, respectively (p < 0.001).

In the univariable analysis outlined in Online Table 1 , older age (≥75 years), history of coronary artery disease, valvular heart disease, COPD, tachypnea, hypotension, altered consciousness, qSOFA score ≥2, use of aspirin on admission, high WBC counts, low lymphocyte percentages, low hemoglobin levels, low albumin levels, renal dysfunction, high creatinine kinase levels, and high D-dimer levels were significantly associated with an increased risk of the primary outcome. T3 was also associated with an increased risk of the primary outcome [hazard ratio (HR) 3.18; 95% confidence interval (CI) 1.78-5.66; p < 0.001].

Multivariable analysis was conducted to determine whether the serum LDH level measured at the time of admission was related to in-hospital death. The multivariable analysis in Model 1 was adjusted for age, history of coronary artery disease, valvular heart disease, COPD, vital signs, renal function, and laboratory data ( Table 2 ). The results also showed that T3 was associated with an increased risk of the primary outcome (adjusted HR 3.04, 95% CI 1.50-6.13, p=0.002). In addition, age ≥75 years, history of COPD, and chronic kidney disease (stage 4 or 5) were independently associated with an increased risk of the primary outcome. Another multivariable analysis was conducted in Model 2 with adjustments for age, qSOFA scores, renal function assessed on admission, WBC counts, lymphocyte counts, and D-dimer, hemoglobin, albumin, CK, and LDH levels on admission ( death. The results remained significant with no effect modification by age and sex (pinteraction >0.05 for both).

In the present study, we investigated the impact of serum LDH level measured at the time of hospital admission on the prognoses of high-risk COVID-19 patients with pre-existing cardiovascular comorbidities. Our results showed that elevated serum LDH level on hospital admission was associated with an increased risk of in-hospital death in patients with COVID-19 and underlying cardiovascular comorbidities. LDH has been reported to predict severe respiratory failure and mortality in patients with COVID-19; however, no study has been conducted to clarify its significance in patients with COVID-19 and cardiovascular comorbidities.

Patients with COVID-19 and underlying cardiovascular disease have poor prognoses [2, 14] . Pre-existing cardiovascular disease seems to be associated with worse outcomes and increased risk of death in patients with COVID-19. The overall case fatality rate of COVID-19 reported by the Chinese Center for Disease Control and Prevention as of February 11, 2020, was 2.3% (1,023 deaths among 44,672 confirmed cases) [1] . The individual case fatality rate for patients with cardiovascular disease was 10.5% [1] . In a report of 1,591 patients with COVID-19 who were admitted to an intensive care unit in Italy, 49% of the patients had pre-existing hypertension, 21% had cardiovascular disease, and 17% had diabetes [15] . COVID-19 not only causes viral pneumonia but also triggers cardiovascular disorders, such as myocardial injury, arrhythmias, acute coronary syndrome, and thromboembolism [16] [17] [18] [19] [20] [21] . The mechanism by which SARS-CoV-2 affects the heart is not clear. Some researchers have suggested that the myocardial injury is secondary to systemic causes, whereas others demonstrated direct viral infection of the heart and subsequent viral myocarditis [22] [23] [24] [25] . Although physicians fear that patients with COVID-19 who have concomitant cardiovascular diseases would have poor prognoses, no criteria that focus on the risk stratification of these patients upon hospital admission have yet been identified. In this study, significantly more patients in the lowest tertile of LDH presented with hypoxia than the patients with higher LDH. As patients with high LDH followed worse prognosis, initial lower percentage of hypoxia was not met with the reasonable explanation. However, since CLAVIS-COVID comprises patients hospitalized for COVID-19, the premise of the study is inclusion of patients with more severe condition than the general population of COVID-19.

The percentage of hypoxic patients in the whole study calculates as high as 97.3%, demonstrating inclusion of patients with severe disease.

As LDH is a cytoplasmic enzyme that is widely expressed in tissues, it could be a useful marker of systemic inflammation. The enzyme converts pyruvate, which is the final product of glycolysis, to lactate when oxygen is in short supply. LDH is present in five separate isozymes (LDH-1 in cardiomyocytes, LDH-2 in the reticuloendothelial system, LDH-3 in pneumocytes, LDH-4 in the kidneys and pancreas, and LDH-5 in the liver and striated muscles) [26, 27] . As it is present in most body cells, LDH is a general indicator of acute or chronic tissue damage and is considered an inflammatory marker [28] . Historically, LDH was first used for the diagnosis of myocardial infarction, as it reflects necrosis of cardiomyocytes.

LDH serum concentrations have been reported to increase during the acute lung damage that occurs in interstitial lung disease and severe respiratory failure [3] . It is also one of the biomarkers most strongly associated with ARDS mortality [4, 5] . In a study of 67 patients with severe ARDS during the epidemic in 2003, multivariate analyses showed that elevated LDH levels (odds ratio 8.4, 95% CI 1.9-36.9) at the time of admission was an independent predictor of ARDS [29] .

LDH has been reported to predict mortality in severe and critically ill patients with COVID-19 [6] . In a pooled analysis of nine published studies that included 1,532 patients with COVID-19, elevated LDH levels were associated with a 6-fold increase in the odds of developing severe disease and a 16-fold increase in the odds of mortality [30] . In a multicenter nested case-control study, advanced age and high LDH level were independent risk factors for deterioration in patients with mild COVID-19 [7] . LDH is also independently associated with one-month mortality in older inpatients with COVID-19 [8] and is a predictor of respiratory failure in hospitalized patients with COVID-19 [9] . A previous study has also shown that elevated LDH level on admission is an independent risk factor for severe COVID-19 [10] .

In the present study, a very high LDH level (LDH >355 U/L) at the time of hospital admission was associated with an increased risk of in-hospital death in patients with COVID-19 and cardiovascular comorbidities. LDH could reflect damage to pneumocytes due to severe respiratory failure and damage to the myocardium and other organs. Measurement of a specific LDH isozyme in future studies would help reveal which tissue is more extensively affected by COVID-19. In the present study, neither high-sensitivity troponin nor D-dimer levels were significantly associated with an increased risk of the primary outcome in the multivariable analysis. On the other hand, as serum LDH level was an independent risk factor for in-hospital death in patients with coexisting cardiovascular diseases, it seemed to be a reliable marker. In addition, since measurement of LDH is generally included in the initial laboratory tests performed on hospital admission and the data can easily be obtained from outpatient clinics and emergency departments, serum LDH level could widely aid physicians in predicting the clinical course of the patients with COVID-19 at the time of admission. The results of the present study have shown the significance of serum LDH level in the assessment of patients with COVID-19 and cardiovascular comorbidities.

First, owing to the retrospective nature of the study, decisions regarding the hospitalization of patients and subsequent initiation of treatment were made by the physicians in the participating medical centers. Because this study was conducted in the early period of the pandemic, medication usage of steroids, antiviral drugs, and immuno-suppressants might differ from the current practice. At the time of the study in early 2020, genetic variants of SARS-CoV-2 had not been as widely observed as in year 2021, which might therefore lead to different results if conducted in the circumstances where most of the infections are caused by genetic variants. Second, only hospitalized patients with COVID-19 were included in the CLAVIS-COVID study. Since only 252 patients had data on brain natriuretic protein (BNP) or N-terminal (NT)-proBNP measured at initial hospitalization, it was not feasible to determine whether BNP or NT-proBNP was a risk factor for the primary outcome. In this observational study, data were collected on the patients' vital signs at admission and flow rate of oxygen administered. However, neither the fraction of inspired oxygen (FiO2) nor type of oxygen delivery device were collected, so it was not possible to calculate PaO2/FiO2, which is commonly used to determine severity of COVID-19. Third, since the primary outcome was in-hospital death, patients were not followed up after discharge; therefore, the long-term prognoses of the patients were not known. Finally, specific LDH isozymes were not evaluated; thus, it is not possible to draw conclusions on which organ was the primary source of tissue damage.

In summary, high serum LDH level measured at the time of admission is associated with an increase in the risk of in-hospital death in patients with COVID-19 and underlying cardiovascular disease. Since measurement of serum LDH is generally included in the initial laboratory tests, the results could aid physicians in predicting the clinical course of patients with COVID-19 and cardiovascular comorbidities. 

The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. Vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) -China

COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives

Serum lactate dehydrogenase in interstitial lung disease

Plasma biomarkers for acute respiratory distress syndrome: a systematic review and metaanalysis*

Albumin rather than Creactive protein may be valuable in predicting and monitoring the severity and course of acute respiratory distress syndrome in critically ill patients with or at risk for the syndrome after new onset fever

Prognostic value of lactate dehydrogenase for in-hospital mortality in severe and critically ill patients with COVID-19

Lactate dehydrogenase and susceptibility to deterioration of mild COVID-19 patients: a multicenter nested casecontrol study

LDH and absence of anticoagulation are independently associated with one-month mortality in older inpatients with Covid-19

Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients

Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study

Clinical and biomarker profiles and prognosis of elderly patients with coronavirus disease 2019 (COVID-19) with cardiovascular diseases and/or risk factors

CDC's Diagnostic Test for COVID-19 Only and Supplies

Oxygenation and Ventilation. Coronavirus disease 2019 (COVID-19) treatment guidelines

Potential effects of coronaviruses on the cardiovascular system: A review

Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical course and mortality risk of severe COVID-19

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

Cardiovascular implications of the COVID-19 pandemic

COVID-19 and cardiovascular diseases

Suspected myocardial injury in patients with COVID-19: Evidence from front-line clinical observation in Wuhan, China

Myocardial localization of coronavirus in COVID-19 cardiogenic shock

Autopsy findings and venous thromboembolism in patients with COVID-19: A prospective cohort study

Postmortem examination of patients with COVID-19

Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells

Serum lactate dehydrogenase isoenzyme and total lactate dehydrogenase values in health and disease, and clinical evaluation of these tests by means of discriminant analysis

Nutrition, metabolism, and cardiovascular disease

Clinical features and outcomes of severe acute respiratory syndrome and predictive factors for acute respiratory distress syndrome

Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis

BMI, body mass index

COPD, chronic obstructive pulmonary disease

C, degrees Celsius; BP, blood pressure; SOFA, sequential organ failure assessment

MRA, mineralocorticoid receptor antagonist

DOAC, direct oral anticoagulant

WBC, white blood cell

CK, creatinine kinase; eGFR, estimated glomerular filtration rate; LDL, low-density lipoprotein